High-dose sirolimus and immune-selective pentostatin plus cyclophosphamide conditioning yields stable mixed chimerism and insufficient graft-versus-tumor responses

Miriam E Mossoba, David C Halverson, Roger Kurlander, Bazetta Blacklock Schuver, Ashley Carpenter, Brenna Hansen, Seth M Steinberg, Syed Abbas Ali, Nishant Tageja, Frances T Hakim, Juan Gea-Banacloche, Claude Sportes, Nancy M Hardy, Dennis D Hickstein, Steven Z Pavletic, Hanh Khuu, Marianna Sabatini, David Stroncek, Bruce L Levine, Carl H June, Jacopo Mariotti, Olivier Rixe, Antonio Tito Fojo, Michael R Bishop, Ronald E Gress, Daniel H Fowler
2015-10-01
Abstract:Purpose: We hypothesized that lymphoid-selective host conditioning and subsequent adoptive transfer of sirolimus-resistant allogeneic T cells (T-Rapa), when combined with high-dose sirolimus drug therapy in vivo, would safely achieve antitumor effects while avoiding GVHD. Experimental Design: Patients (n = 10) with metastatic renal cell carcinoma (RCC) were accrued because this disease is relatively refractory to high-dose conditioning yet may respond to high-dose sirolimus. A 21-day outpatient regimen of weekly pentostatin (P; 4 mg/m2/dose) combined with daily, dose-adjusted cyclophosphamide (C; ≤200 mg/d) was designed to deplete and suppress host T cells. After PC conditioning, patients received matched sibling, T-cell–replete peripheral blood stem cell allografts, and high-dose sirolimus (serum trough target, 20–30 ng/mL). To augment graft-versus-tumor (GVT) effects …
What problem does this paper attempt to address?